The continual reassessment method in cancer phase I clinical trials: a simulation study
Related Experiment Video
Updated: Oct 13, 2026

Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement
Published on: July 29, 2013
1Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris, France.
Abstract:
In cancer studies, the aim of phase I clinical trials is to identify an appropriate dose for experimentation in phase II and III studies. The continual reassessment method (CRM) has been developed recently and presented as the method of choice in the design and analysis of such phase I studies. However, to implement the method, some methodological and practical considerations must be addressed. This paper examines, through a simulation study, the sensitivity of CRM both to the initial modelling of the dose-toxicity relationship and the prior. It appears that the performance of CRM can be improved by using vague priors and initial tuning of the model to allow flexibility.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Preclinical Development: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Kaplan-Meier Approach
Cancer Survival Analysis

